Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;48(7):2349-2360.
doi: 10.1007/s00261-023-03882-5. Epub 2023 Apr 18.

Diagnostic performance of multiparametric magnetic resonance imaging in the differentiation of clear cell renal cell cancer

Cemal Aydoğan  1 , Ayşegül Cansu  2 , Zeynep Aydoğan  2 , Sinan Erdemi  3 , Aykut Teymur  4 , Onur Bektaş  2 , Sevdegül Mungan  5 , İlke Onur Kazaz  6
Affiliations

Diagnostic performance of multiparametric magnetic resonance imaging in the differentiation of clear cell renal cell cancer

Cemal Aydoğan et al. Abdom Radiol (NY). 2023 Jul.

Abstract

Purpose: This study aimed to evaluate the diagnostic performance of multiparametric magnetic resonance imaging (mpMRI) in the differentiation of renal cell carcinoma (RCC) subtypes.

Methods: This is a retrospective diagnostic performance study, in which the diagnostic performances of mpMRI features were evaluated to differentiate clear cell RCC (ccRCC) from non-clear cell RCC (non-ccRCC). Adult patients who were evaluated using a 3-Tesla dynamic contrast-enhanced mpMRI before undergoing partial or radical nephrectomy for possible malignant renal tumors were included in the study. Signal intensity change percentages (SICP) between contrast-enhanced phases and pre-administration period for both the tumor and normal renal cortex, and tumor-to-cortex enhancement index (TCEI); tumor apparent diffusion coefficient (ADC) values; tumor-to-cortex ADC ratio; and a scale which was developed according to the tumor signal intensities on the axial fat-suppressed T2-weighted Half-Fourier Acquisition Single-shot Turbo spin Echo (HASTE) images were used in ROC analysis to estimate the presence of ccRCC in the patients. The reference test positivity was the histopathologic examination of the surgical specimens.

Results: Ninety-eight tumors from 91 patients were included in the study, and 59 of them were ccRCC, 29 were pRCC, and 10 were chRCC. The mpMRI features that had the three highest sensitivity rates were excretory phase SICP, T2-weighted HASTE scale score, and corticomedullary phase TCEI (93.2%, 91.5%, and 86.4%, respectively). However, those with the three highest specificity rates were nephrographic phase TCEI, excretory phase TCEI, and tumor ADC value (94.9%, 94.9%, and 89.7%, respectively).

Conclusion: Several parameters on mpMRI showed an acceptable performance to differentiate ccRCC from non-ccRCC.

Keywords: Chromophobe renal cell carcinoma; Clear cell renal cell carcinoma; Differential diagnosis; Multiparametric magnetic resonance imaging; Papillary renal cell carcinoma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Gurel S, Narra V, Elsayes KM, Siegel CL, Chen ZE, Brown JJ (2013) Subtypes of renal cell carcinoma: MRI and pathological features. Diagnostic and Interventional Radiology. https://doi.org/10.5152/dir.2013.147 - DOI - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72 (1):7-33. https://doi.org/10.3322/caac.21708 - DOI - PubMed
    1. Sun MR, Ngo L, Genega EM, Atkins MB, Finn ME, Rofsky NM, Pedrosa I (2009) Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. Radiology 250 (3):793-802. https://doi.org/10.1148/radiol.2503080995 - DOI - PubMed
    1. Pal SK, Tangen C, Thompson IM, Jr., Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN, Jr. (2021) A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet 397 (10275):695-703. https://doi.org/10.1016/s0140-6736(21)00152-5 - DOI - PubMed - PMC
    1. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grunwald V, Gillessen S, Horwich A, clinicalguidelines@esmo.org EGCEa (2019) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 30 (5):706-720. https://doi.org/10.1093/annonc/mdz056 - DOI - PubMed

LinkOut - more resources